AEST.MED.INT.HLD.SP.ADR/3 (3FMA) - Total Assets
Based on the latest financial reports, AEST.MED.INT.HLD.SP.ADR/3 (3FMA) holds total assets worth €510.89 Million EUR (≈ $597.29 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check AEST.MED.INT.HLD.SP.ADR/3 (3FMA) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
AEST.MED.INT.HLD.SP.ADR/3 - Total Assets Trend (2021–2025)
This chart illustrates how AEST.MED.INT.HLD.SP.ADR/3's total assets have evolved over time, based on quarterly financial data. Explore investment intensity of AEST.MED.INT.HLD.SP.ADR/3 to see how much of total assets are deployed in long-term investments.
AEST.MED.INT.HLD.SP.ADR/3 - Asset Composition Analysis
Current Asset Composition (December 2025)
AEST.MED.INT.HLD.SP.ADR/3's total assets of €510.89 Million consist of 26.3% current assets and 73.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 11.8% |
| Accounts Receivable | €6.40 Million | 1.3% |
| Inventory | €18.80 Million | 3.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.31 Million | 0.5% |
| Goodwill | €29.28 Million | 5.7% |
Asset Composition Trend (2021–2025)
This chart illustrates how AEST.MED.INT.HLD.SP.ADR/3's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 3FMA market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AEST.MED.INT.HLD.SP.ADR/3's current assets represent 26.3% of total assets in 2025, an increase from 19.7% in 2021.
- Cash Position: Cash and equivalents constituted 11.8% of total assets in 2025, up from 6.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, unchanged from 5.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 5.7% of total assets.
AEST.MED.INT.HLD.SP.ADR/3 Competitors by Total Assets
Key competitors of AEST.MED.INT.HLD.SP.ADR/3 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fresenius Medical Care AG & Co. KGaA
XETRA:FME
|
Germany | €31.47 Billion |
|
Ramsay Health Care Ltd
AU:RHC
|
Australia | AU$21.70 Billion |
|
PACS Group, Inc.
NYSE:PACS
|
USA | $5.66 Billion |
|
RAMSAY HLTH.CARE ADR/025
F:RMY0
|
Germany | €22.48 Billion |
|
Top Choice Medical Investment Co Inc
SHG:600763
|
China | CN¥6.24 Billion |
|
Sanbo Hospital Management Group Ltd. A
SHE:301293
|
China | CN¥3.72 Billion |
|
Xian International Medical Investment Co Ltd
SHE:000516
|
China | CN¥9.50 Billion |
|
MLP Saglik Hizmetleri AS
IS:MPARK
|
Turkey | TL89.94 Billion |
AEST.MED.INT.HLD.SP.ADR/3 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.31 | 0.22 | 0.24 |
| Quick Ratio | 0.27 | 0.18 | 0.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-294.15 Million | €-313.96 Million | €-315.49 Million |
AEST.MED.INT.HLD.SP.ADR/3 - Advanced Valuation Insights
This section examines the relationship between AEST.MED.INT.HLD.SP.ADR/3's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.96 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 5.1% |
| Total Assets | €510.89 Million |
| Market Capitalization | $3.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values AEST.MED.INT.HLD.SP.ADR/3's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: AEST.MED.INT.HLD.SP.ADR/3's assets grew by 5.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for AEST.MED.INT.HLD.SP.ADR/3 (2021–2025)
The table below shows the annual total assets of AEST.MED.INT.HLD.SP.ADR/3 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €510.89 Million ≈ $597.29 Million |
+5.07% |
| 2024-12-31 | €486.22 Million ≈ $568.45 Million |
-13.28% |
| 2023-12-31 | €560.66 Million ≈ $655.48 Million |
+2.62% |
| 2022-12-31 | €546.37 Million ≈ $638.76 Million |
-5.30% |
| 2021-12-31 | €576.94 Million ≈ $674.50 Million |
-- |
About AEST.MED.INT.HLD.SP.ADR/3
Aesthetic Medical International Holdings Group Limited provides aesthetic medical services in the People's Republic of China. The company offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments, including minimally invasive and energy-based treatments, which include laser, ultrasound, and radiofrequency tr… Read more